<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672928</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI318C302</org_study_id>
    <nct_id>NCT04672928</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies</brief_title>
  <official_title>A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase Ib/III clinical study to evaluate the efficacy and safety of&#xD;
      recombinant fully human anti-programmed cell death receptor 1 (PD-1) and anti-programmed cell&#xD;
      death ligand 1 (PD-L1) bispecific antibody injection (IBI318) in combination with paclitaxel&#xD;
      versus placebo in combination with paclitaxel in subjects with small cell lung cancer who&#xD;
      have failed first-line or above chemotherapies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 21, 2020</start_date>
  <completion_date type="Anticipated">November 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>The incidence rate of all treatment-emergent adverse events (TEAEs), immune-related adverse events (irAEs) and serious adverse events (SAEs), treatment-related adverse events (TRAEs) and the severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective remission rate</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of subjects with complete response (CR) or partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous remission time (DOR)</measure>
    <time_frame>12 months</time_frame>
    <description>For subjects with CR or PR, it is defined as the time from the first documented objective tumor response (CR or PR) to objective disease progression (PD) or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of subjects with complete response (CR), partial response (PR), or stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>12 months</time_frame>
    <description>Time from randomization to first objective tumor response (CR or PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as the time from randomization to the first occurrence of objective disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>IBI318 in combination with paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel injection</description>
    <arm_group_label>IBI318 in combination with paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>lBI318 injection</description>
    <arm_group_label>IBI318 in combination with paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed the Informed Consent Form;&#xD;
&#xD;
          2. Male or female ≥ 18 and≤75 years of age;&#xD;
&#xD;
          3. Life expectancy ≥ 12 weeks;&#xD;
&#xD;
          4. Pathologically confirmed limited or extensive stage small cell lung cancer according&#xD;
             to Veterans Lung Administration Lung Study Group (VALG) staging;&#xD;
&#xD;
          5. At least had progressive disease during or after platinum-based first-line&#xD;
             chemotherapy or chemoradiotherapy, and with clear evidence of radiographic&#xD;
             progression.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous exposure to immune-mediated therapy; previous use of taxane chemotherapy;&#xD;
&#xD;
          2. Received the last anti-tumor therapy (chemotherapy, radiotherapy) within 4 weeks prior&#xD;
             to the first dose of study drug;&#xD;
&#xD;
          3. Received any investigational agent within 4 weeks prior to the first dose of study&#xD;
             drug;&#xD;
&#xD;
          4. Received systemic treatment with Chinese herbal medicine indicated for cancer or drugs&#xD;
             used for immunoregulation (including thymosin, interferon, interleukin, except for&#xD;
             local use for pleural effusion) within 2 weeks before the first dose;&#xD;
&#xD;
          5. Are participating in another interventional clinical study, or observational&#xD;
             (non-interventional) clinical study or in the follow-up phase of an interventional&#xD;
             study;&#xD;
&#xD;
          6. Pregnant or breastfeeding woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Cheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jilin Provincial Tumor Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuanmi Chai</last_name>
    <phone>0512-69566088</phone>
    <email>yuanmi.chai@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences.</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Wang</last_name>
      <phone>010-67781331</phone>
      <email>zlhuxi@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Cheng</last_name>
      <phone>0431-80596315</phone>
      <email>jl.cheng@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

